Delcath Systems Inc. (NASDAQ: DCTH)
$11.2350
-0.2050 ( -1.45% ) 78.1K
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Data
Open
$11.2350
Previous close
$11.4400
Volume
78.1K
Market cap
$360.50M
Day range
$11.1500 - $11.6700
52 week range
$3.7000 - $13.3011
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 93 | Nov 08, 2024 |
8-k | 8K-related | 14 | Nov 08, 2024 |
4 | Insider transactions | 1 | Nov 01, 2024 |
4 | Insider transactions | 1 | Nov 01, 2024 |
4 | Insider transactions | 1 | Nov 01, 2024 |
4 | Insider transactions | 1 | Oct 23, 2024 |
8-k | 8K-related | 14 | Oct 17, 2024 |
8-k | 8K-related | 14 | Aug 29, 2024 |
8-k | 8K-related | 17 | Aug 28, 2024 |
10-q | Quarterly Reports | 92 | Aug 05, 2024 |